FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366239112> ?p ?o ?g. }

• W4366239112 endingPage "1549" @default.
• W4366239112 startingPage "1540" @default.
• W4366239112 abstract "The effectiveness of gemcitabine-based adjuvant chemotherapy is unclear in cholangiocarcinoma. We investigated the role of adjuvant gemcitabine plus cisplatin (GemCis) in a homogeneous group of high-risk patients with resected, lymph node-positive extrahepatic cholangiocarcinoma.Adenocarcinoma of perihilar or distal bile duct with regional lymph node metastasis who underwent curative-intent surgery (R0/R1) was eligible. Patients were randomized to receive GemCis (gemcitabine 1000 mg/m2, cisplatin 25 mg/m2 on days 1 and 8) or capecitabine (1250 mg/m2 twice daily on days 1-14) every 3 weeks for 8 cycles. Primary endpoint was disease-free survival. Secondary endpoints were overall survival and safety. All p values are 1 sided and were considered significant if <0.1. Between July 2017 and November 2020, 101 patients (50 in the GemCis and 51 in the capecitabine group) were included in the intention-to-treat population. Perihilar and distal bile ducts were the primary sites in 45 (44.6%) and 56 (55.4%) patients, respectively, and 32 (31.7%) had R1 resections. Median (1-sided 90% CI) follow-up duration was 33.4 (30.5-35.8) months. In the GemCis and capecitabine group, 2-year disease-free survival rates were 38.5% (29.5%-47.4%) and 25.1% (17.4%-33.5%) [HR=0.96 (CI, 0.71-1.30), p=0.430], and median overall survival was 35.7 months (29.5-not estimated) and 35.7 months (30.9-not estimated) [HR=1.08 (CI, 0.71-1.64), 1-sided p=0.404], respectively. Grade 3-4 adverse events occurred in 42 (84.0%) and 8 patients (16.0%) in the GemCis and capecitabine groups, respectively. No treatment-related deaths were reported.In resected lymph node-positive extrahepatic cholangiocarcinoma, adjuvant GemCis did not improve survival outcomes compared with capecitabine." @default.
• W4366239112 created "2023-04-20" @default.
• W4366239112 creator A5004673227 @default.
• W4366239112 creator A5008140107 @default.
• W4366239112 creator A5023344582 @default.
• W4366239112 creator A5035547791 @default.
• W4366239112 creator A5037596654 @default.
• W4366239112 creator A5042325100 @default.
• W4366239112 creator A5050625196 @default.
• W4366239112 creator A5052369288 @default.
• W4366239112 creator A5065909568 @default.
• W4366239112 creator A5066759908 @default.
• W4366239112 creator A5070944685 @default.
• W4366239112 creator A5077803036 @default.
• W4366239112 creator A5085507554 @default.
• W4366239112 creator A5090754319 @default.
• W4366239112 date "2023-01-03" @default.
• W4366239112 modified "2023-10-17" @default.
• W4366239112 title "Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial" @default.
• W4366239112 cites W1486884945 @default.
• W4366239112 cites W1991781466 @default.
• W4366239112 cites W2002960783 @default.
• W4366239112 cites W2034770797 @default.
• W4366239112 cites W2039961595 @default.
• W4366239112 cites W2059922433 @default.
• W4366239112 cites W2115261608 @default.
• W4366239112 cites W2124474327 @default.
• W4366239112 cites W2141078344 @default.
• W4366239112 cites W2146621833 @default.
• W4366239112 cites W2148899606 @default.
• W4366239112 cites W2157499993 @default.
• W4366239112 cites W2790277876 @default.
• W4366239112 cites W2914858130 @default.
• W4366239112 cites W2923282967 @default.
• W4366239112 cites W2937317161 @default.
• W4366239112 cites W3010944770 @default.
• W4366239112 cites W3013978214 @default.
• W4366239112 cites W3024247862 @default.
• W4366239112 cites W4206434444 @default.
• W4366239112 cites W4225679537 @default.
• W4366239112 cites W4281630496 @default.
• W4366239112 cites W4317488871 @default.
• W4366239112 doi "https://doi.org/10.1097/hep.0000000000000046" @default.
• W4366239112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37070950" @default.
• W4366239112 hasPublicationYear "2023" @default.
• W4366239112 type Work @default.
• W4366239112 citedByCount "3" @default.
• W4366239112 countsByYear W43662391122023 @default.
• W4366239112 crossrefType "journal-article" @default.
• W4366239112 hasAuthorship W4366239112A5004673227 @default.
• W4366239112 hasAuthorship W4366239112A5008140107 @default.
• W4366239112 hasAuthorship W4366239112A5023344582 @default.
• W4366239112 hasAuthorship W4366239112A5035547791 @default.
• W4366239112 hasAuthorship W4366239112A5037596654 @default.
• W4366239112 hasAuthorship W4366239112A5042325100 @default.
• W4366239112 hasAuthorship W4366239112A5050625196 @default.
• W4366239112 hasAuthorship W4366239112A5052369288 @default.
• W4366239112 hasAuthorship W4366239112A5065909568 @default.
• W4366239112 hasAuthorship W4366239112A5066759908 @default.
• W4366239112 hasAuthorship W4366239112A5070944685 @default.
• W4366239112 hasAuthorship W4366239112A5077803036 @default.
• W4366239112 hasAuthorship W4366239112A5085507554 @default.
• W4366239112 hasAuthorship W4366239112A5090754319 @default.
• W4366239112 hasConcept C121608353 @default.
• W4366239112 hasConcept C126322002 @default.
• W4366239112 hasConcept C141071460 @default.
• W4366239112 hasConcept C143998085 @default.
• W4366239112 hasConcept C168563851 @default.
• W4366239112 hasConcept C203092338 @default.
• W4366239112 hasConcept C2776694085 @default.
• W4366239112 hasConcept C2777909004 @default.
• W4366239112 hasConcept C2778239845 @default.
• W4366239112 hasConcept C2780258809 @default.
• W4366239112 hasConcept C2908647359 @default.
• W4366239112 hasConcept C526805850 @default.
• W4366239112 hasConcept C71924100 @default.
• W4366239112 hasConcept C90924648 @default.
• W4366239112 hasConcept C99454951 @default.
• W4366239112 hasConceptScore W4366239112C121608353 @default.
• W4366239112 hasConceptScore W4366239112C126322002 @default.
• W4366239112 hasConceptScore W4366239112C141071460 @default.
• W4366239112 hasConceptScore W4366239112C143998085 @default.
• W4366239112 hasConceptScore W4366239112C168563851 @default.
• W4366239112 hasConceptScore W4366239112C203092338 @default.
• W4366239112 hasConceptScore W4366239112C2776694085 @default.
• W4366239112 hasConceptScore W4366239112C2777909004 @default.
• W4366239112 hasConceptScore W4366239112C2778239845 @default.
• W4366239112 hasConceptScore W4366239112C2780258809 @default.
• W4366239112 hasConceptScore W4366239112C2908647359 @default.
• W4366239112 hasConceptScore W4366239112C526805850 @default.
• W4366239112 hasConceptScore W4366239112C71924100 @default.
• W4366239112 hasConceptScore W4366239112C90924648 @default.
• W4366239112 hasConceptScore W4366239112C99454951 @default.
• W4366239112 hasIssue "5" @default.
• W4366239112 hasLocation W43662391121 @default.
• W4366239112 hasLocation W43662391122 @default.
• W4366239112 hasOpenAccess W4366239112 @default.
• W4366239112 hasPrimaryLocation W43662391121 @default.

• next